AI PRICE FORECAST
PFE Stock Forecast & AI Price Prediction
Pfizer · Healthcare · Drug Manufacturers - General
PFE live signal snapshot
Shares of PFE were last at $29.45, up 0.31% on the day, trading 6.3% below its 52-week high of $31.44 and 24.7% above its 52-week low of $23.62. Stock Pulse 247's AI model currently rates PFE a HOLD, at 72% model confidence. The technical signals aren't aligned enough for a directional call yet. The short-term averages are tangled, giving no clean trend signal either way. Its one-month projection is about $28.70, a -2.5% move from the last price.
PFE's 14-day RSI is 44.3 — approaching oversold, suggesting weakening momentum. The MACD indicator trails its signal line, with a histogram of -0.16 pointing to selling pressure. With the 50-day average at $28.80, 6.9% over the 200-day's $26.96, the longer-term trend structure remains positive.
26 Wall Street analysts covering PFE put the average price target at $30.22 (range $25.00–$37.00), implying 2.6% upside from the current price. The current recommendation trend leans bullish: 9 Buy/Strong Buy ratings vs 2 Sell/Strong Sell (and 17 Hold).
Live figures from real market data feeds, current as of the last site build. Open the interactive PFE dashboard for numbers updated throughout today's session.
About Pfizer
Pfizer Inc. (PFE) is a drug manufacturers - general company in the healthcare sector, headquartered in New York, NY, United States. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It has a market value of about $167.9 billion and roughly 75,000 full-time employees. With a beta of 0.3, the stock has historically moved less than the overall market.
PFE performance vs. the market
Since the start of 2026 the stock has risen 18.3%, ahead of the S&P 500 (+11.4%) and behind the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has gained 20.7%, 9.2 points better than the S&P 500. Its +3.8% move over the past month extends a +9.9% three-month run.
| Period | PFE | Sector (XLV) | S&P 500 |
|---|---|---|---|
| 1 month | +3.8% | +11.4% | −2.3% |
| 3 months | +9.9% | +12.2% | −2.3% |
| Year to date | +18.3% | +22.1% | +11.4% |
| 1 year | +20.7% | +28.3% | +11.5% |
Pfizer financials at a glance
Pfizer's most recent quarter (ended Sep 30, 2026) brought in $16.6 billion of revenue and net income of $3.2 billion (a 19.6% net margin). Revenue was down 0.4% from the same quarter a year earlier. The stock trades at a price-to-earnings ratio of 42.1 on trailing earnings of $0.70 per share. Trailing free cash flow was $13.0 billion, and total debt equals 71% of shareholders' equity.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Sep 30, 2026 | $16.6B | $3.2B |
| Jun 30, 2026 | $15.0B | −$248M |
| Mar 31, 2026 | $14.5B | $2.7B |
| Dec 31, 2025 | $17.6B | −$1.6B |
PFE vs. its peers
PFE's +18.3% this year ranks ahead of 0 of the 5 big healthcare names below. The strongest of the group this year is Amgen (AMGN, +43.0%).
| Company | Price | YTD | P/E | AI verdict |
|---|---|---|---|---|
| Pfizer (PFE) | $29.45 | +18.3% | 42.1 | HOLD |
| Eli Lilly and (LLY) | $1,437.29 | +33.7% | 46.7 | BUY |
| Johnson & Johnson (JNJ) | $280.41 | +35.5% | 42.6 | BUY |
| AbbVie (ABBV) | $294.98 | +29.1% | 50.7 | BUY |
| Merck & Co. (MRK) | $147.18 | +39.8% | 148.7 | HOLD |
| Amgen (AMGN) | $468.11 | +43.0% | 27.1 | BUY |
PFE stock: common questions
What is the PFE stock price target?
26 Wall Street analysts put the average 12-month target at $30.22, in a range of $25.00–$37.00, versus a recent price of $29.45. Stock Pulse 247's model projects about $28.70 over the next month.
Is PFE a buy right now?
Our AI model currently rates PFE a HOLD at 72% confidence. Among analysts, 9 rate it Buy or Strong Buy, 17 Hold and 2 Sell. Neither is personal advice — weigh them with your own research and risk tolerance.
How has PFE stock performed this year?
Since the start of 2026 the stock has risen 18.3%, ahead of the S&P 500 (+11.4%) and behind the healthcare sector fund XLV (+22.1%). Over the past 12 months the stock has gained 20.7%, 9.2 points better than the S&P 500. Its +3.8% move over the past month extends a +9.9% three-month run.
What is PFE's 52-week high and low?
PFE has traded between $23.62 and $31.44 over the past 52 weeks; at $29.45 it is 6.3% below its 52-week high of $31.44 and 24.7% above its 52-week low of $23.62.
What sector is PFE in, and who are its peers?
PFE is in the healthcare sector (drug manufacturers - general). Its largest peers on Stock Pulse 247 include Eli Lilly and (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co. (MRK).
How accurate is the PFE forecast?
It's a model estimate from price history, technical indicators and analyst targets, not a guarantee — no model predicts short-term moves reliably. Use it as one input alongside your own research.
How this works: the forecast combines PFE's price history, momentum indicators (RSI, MACD, moving averages), volatility and analyst targets into one estimate. It's a model, not a guarantee.